∇⋅B = 0 (@maxwelllove_) header
∇⋅B = 0 (@maxwelllove_) profile picture

Co-founder, CEO https://nitter.cf/t.co/7NjCbYXsNn

San Francisco, CA
Joined February 2019
Photo by ∇⋅B = 0 (@maxwelllove_)Photo by ∇⋅B = 0 (@maxwelllove_)
The bio-native wet lab founder in 2026 is exactly where the ex-lab AI infra founder was in 2024
97
Great night AI-pilling some of my personal heroes
9
2
2
103
19,158
Alphafold's "predicted structures remain invariant to mutations of up to 40% of residues ... and to deletions of 10%, even for proteins known to adopt alternative conformations." If this is worth $50b, how much is thermodynamic awareness worth? icml.cc/virtual/2026/78902
691
Verification is expensive because it's bounded by the physical world ie. what you can glean from a biological assay. Whoever figures out how to scale beyond the physical world without excessively compromising on fidelity and resolution will change the world.
Frontier labs are moving into drug discovery and preclinical work, but not mainly to build their own therapeutics. They are entering because biology is the hardest RL environment around: slow feedback, noisy results, no answer key. Verification is expensive, so what's really being tested is how a model acts under uncertainty. If a model can do good science, that carries over to R&D, the engine driving growth across the rest of the economy.
3
3
12
3,985
Agree that insight into chemistry, among other applied sciences, is needed for meaningful AI drug development The reason that chemistry appears ignored is because there is no public PDB equivalent in chemistry So I'd push back and say that the chemical frontier is more a data problem than a myopia problem
[some unfiltered personal thoughts] On the state of play of the frontier intelligence labs when it comes to AI x Science: I find extremely puzzling the fact that there is little to no attention to chemistry. at least not publicly. I cannot comprehend how any organization that aims to “cure all diseases” or develop general technology to benefit society can be so myopic when it comes to the central science.
1
537
This is quite literally an average Tuesday for Okezue
My first results in spectral theory: - Spectral-to-tiling direction of Fuglede's conjecture holds in 4 intervals arxiv.org/abs/2610.37975 - Extended this to five intervals, then arbitrarily many intervals with at most four independent rational relations among their lengths arxiv.org/abs/2611.00307
3
423
Over the last 24 hours, I've spoken with three partners at leading biopharma funds. Two of them didn't recognize frontier labs as disruptive to pharma at all. If the impact of AI on drug development is nonzero, then the alpha in techbio is unprecedented.
2
222
This is an awesome chart Maxx. Clearly shows how investor attitudes have shifted in recent years. I'm still not sold that AI will make a great drug hunter. Is predicting human biology really a data problem? I can be easily convinced, just haven't seen compelling evidence yet.
ARE AI DRUG DISCOVERY STARTUPS ACTUALLY BETTER? So far, there's surprisingly no clear link between clinical output and AI use, total capital funding, or founding date. But protein-focused startups seem to outperform DNA and RNA-based approaches. Full-version with detailed tooltip data here: datawrapper.de/_/mPrYd/
1
1
445
∇⋅B = 0 retweeted
Some updates from our team at @thecollectiv3e - we've been growing fast! 1. We're opening our NYC HQ in Chelsea. A 6,000 sqft loft in the heart of the city. This will be the premier space for founders and builders in New York. There are very few good coworking spaces in NYC - we want to change that. We're designing our space to be the best place for founders and builders in the city. We'll have private offices, a maker-space, a content room, a kitchen, a lounge, and much more. 2. We launched our talent arm. From the beginning, we've specialized in finding exceptional people and bringing them together. For a long time that meant events and community. Now we're applying the same approach to hiring. We believe great hires come from in-person relationships and a deeply trusted network. We're excited that @clairajv recently joined us as our Founding Head of Talent. She'll be helping members find the right people to supercharge their teams. 3. The community & team is growing quickly! Our latest group, Cohort 4, filled up in 3 weeks (our fastest ever) and we received over 450+ applications during that time period. We recently launched in LA and are happy to see the community coming together nicely. We're also pumped to welcome new fellows to the team across SF, NYC, and LA - @mikashimmura, @maxlovestweets, @Rick_Yang2, @jaydenxxia, @allixzheng, @Davexyao, @l1frances, @ssarahfann, and @BoitDarley. We've come a long way in 12 months, but it feels like we're just getting started. Massive shoutout to all of our members, our partners, and everyone who has supported us so far!
35
10
181
13,930
Introducing our fellows at The Collective! We're excited to welcome new faces across NYC, SF & LA and to congratulate our new city leads, @risashimmura, @k2briian, @FinnStaeblein, @olivialiu82, and Nick. New York: Rick: Harvard, Picus Capital @miraya_j: UIUC, Dorm Room Fund @sidr29: Columbia, founder Stealth @TanejaPriyal: McMaster, MoTS E3 Group @dingdongtinz: Columbia, Dorm Room Fund @mikashimmura: Parsons, Cartier, ex-Hermès @tinajyao: UVA, Girls Who Innovate, content creator @michelletliu: UCLA, sundays in la, 8VC, Figma, Apple @ichristinew: Boston College, content creator (267k+) San Francisco: @allixzheng: Cornell, Uber @Davexyao: UC Berkeley, Blackstone Jayden: UCSD, Product at Solace, Lawnly @maxlovestweets: UC Berkeley, Centerview @lindictive: NYU, ex-founder, Growth at Scope @createdbymason: UC Berkeley, Hackathon Company of California Los Angeles: @Sarah___Fan: USC, GTM Lemma, ex-Photon @ssarahfann: USC, ex-SpaceX, Anduril, 8VC @boitdarley: Harvard, The TerraCotta Group Frances: USC, Permanent Capital Ventures @thecollectiv3e exists to build spaces for ambitious young people changing the world. This is the strongest group we've ever brought together, and we can't wait to see what they do next. Congrats to each one of them!
14
11
2
52
6,804
I don't think anyone is looking to 10x their check at $10b. Moreso it is probably seen as: 1) an opportunity to deploy a large number of absolute dollars 2) make 40% IRR via a 2x+ bump (not 10x) on the next round in under 2 years cc Etched, Instinct etc
$1B on 10B pre-revenue round math: 10-yr hold, 5% employee dilution a year + 50% from funding. GP retains ~30% of initial ownership. To make 10x on the check, the company is worth ~$334B, not $100B. 10x gross becomes ~6x net to the LP. So, inside 10 years, you are building Databricks + Ramp, OpenAI or Anthropic.
4
600
If you are suggesting that we cut off American vc then you are also suggesting that Chinese biotechs should instead license P2 rdy assets to European sponsors. Such a regime would also support profits from Chinese innovation flowing out of US (more layoffs) to European pharma
Biotech VCs going to China will see this and feel nothing for the employees and their families affected They’ll say it’s about cures while they fund a me-three
1
3
717
The lack of efficacy data for many mainstream peptides exists not due to a lack of trying.
1
1
194
Given that biology is a lot harder to monetize at the scale that venture demands, it selects for founders who are building for reasons other than raising lots of money.
I did my 5th deal in bio last week, and I suspect I will be doing much more of it going forward as a non-traditional bio investor, how I got here: > organically met founders using technologies I have a track record of investing in (e.g. robotics, AI), but applied to bio problem spaces > founders doing this seemed stand-out smart, so decided to explore whether this hypothesis of extremely smart founders building in bio is correct (by meeting more across the board) > confirm hypothesis + majority of the most insane pitches I've heard in the last 6 months were from bio founders. tl;dr weird, highly impactful (and probably undervalued) is abundant in bio what I'm currently most interested in (largely moving upstream to the molecular level of themes I've already been investing in): > new molecules (e.g. material sciences or industrial bio). largely upstream from the fund's main thematic focus of investing in physical tech (e.g. new computing surfaces) on a molecular level i.e. manipulating atoms > lab automation (basically a nexus with existing investing in robotics etc, though idk how many bets there are to make here) > "superman" thesis i.e. moonshots that enable superhuman care for or capabilities in the human body (my last investment was here). a molecular evolution of investing in tech that augments human capability (I assume these interest areas will evolve quickly)
2
371
Meet Context, the first AI office suite. Humanity spends 2.5 trillion hours a year on office work. Context can one-shot most of it. Welcome to the era of vibe-working. Sign up today or tag @contextsuite with a prompt.
3,068
987
161
5,560
7,713,522
∇⋅B = 0 retweeted
The biggest barrier in biotech innovation and capital markets is still the lack of a predictable, rapid, patient-focussed regulatory paradigm. Major reforms are needed asap to speed drug regulatory approvals or our lead in biotech will diminish.
20
23
4
196
25,096
Easiest pivot ever
if you’re in software, pivot to biology
318
Today brought new progress in the battle against disease. I see it because I'm in the biotech weeds. Every day brings something new, actually. Americans should take pride in what they make possible w/ just 8% of their healthcare dollars. We're all patients, eventually. 1/3
5
36
4
133
26,327
Tell ma I made it
1
173